Nonetheless, the combined targeting of NF-κB and STAT3 offers a promising approach for the management of liver cancer such as HCC, necessitating further compelling experiments to confirm the robustness of vinpocetine’s effects. This evidence concerns the gene NFKB1 and liver cancer.